MS

Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?
Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?
Endpoints
Biogen
MS
multiple sclerosis
Tecfidera
ALKS 8700
Vumerity
Alkermes
Flag link:
German Merck finally gets yes for MS drug Mavenclad
German Merck finally gets yes for MS drug Mavenclad
Biopharma Dive
FDA
Merck KGaA
Mavenclad
MS
multiple sclerosis
Flag link:
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Fierce Biotech
Celgene
ozanimod
MS
multiple sclerosis
Flag link:
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
Investors Business Daily
Celgene
Novartis
ozanimod
MS
multiple sclerosis
patents
Bristol-Myers Squibb
M&A
Flag link:
GeNeuro finds path forward for temelimab in non-active progressive MS
GeNeuro finds path forward for temelimab in non-active progressive MS
BioCentury
GeNeuro
MS
temelimab
Flag link:
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Xconomy
Celgene
Bristol-Myers Squibb
Europe
FDA
M&A
MS
multiple sclerosis
ozanimod
Flag link:
New insight into how Biogen's Tecfidera works may lead to better MS therapies
New insight into how Biogen's Tecfidera works may lead to better MS therapies
Fierce Biotech
Biogen
Tecfidera
MS
multiple sclerois
R&D
Flag link:
FDA Accepts for Review Alkermes' and Biogen's NDA for Multiple Sclerosis Drug
FDA Accepts for Review Alkermes' and Biogen's NDA for Multiple Sclerosis Drug
CP WIre
Alkermes
Biogen
diroximel fumarate
MS
multiple sclerosis
Flag link:
Pair of deals boosts Biogen’s early-stage CNS pipeline
Pair of deals boosts Biogen’s early-stage CNS pipeline
Pharmaforum
Biogen
CNS
Alzheimer's disease
MS
C4 Therapeutics
Skyhawk Therapeutics
Flag link:
Blocking brain inflammation in multiple sclerosis with gut immune cells
Blocking brain inflammation in multiple sclerosis with gut immune cells
Fierce Biotech
inflammation
MS
multiple sclerosis
Flag link:
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
Flag link:
Alkermes/Biogen hope for less tummy trouble with new MS pill
Alkermes/Biogen hope for less tummy trouble with new MS pill
Pharmaforum
Alkermes
Biogen
MS
multiple sclerosis
Vumerity
Flag link:
FDA hits Sanofi's struggling Lemtrada with new safety warning over reports of stroke, artery tears
FDA hits Sanofi's struggling Lemtrada with new safety warning over reports of stroke, artery tears
Fierce Pharma
Sanofi
Lemtrada
FDA
stroke
MS
Flag link:
Novartis confident in Gilenya despite FDA call out
Novartis confident in Gilenya despite FDA call out
Biopharma Dive
Novartis
Gilenya
MS
multiple sclerosis
Flag link:
Forward Pharma loses appeal in Tecfidera patent dispute with Biogen
Forward Pharma loses appeal in Tecfidera patent dispute with Biogen
Reuters
Biogen
Tecfidera
MS
Forward Pharma
Flag link:
Mylan's generic Copaxone wins in court, but market barriers remain
Mylan's generic Copaxone wins in court, but market barriers remain
Biopharma Dive
Teva Pharmaceutical
Copaxone
patents
MS
multiple sclerosis
Flag link:
Merck KGaA posts mixed data from their big PhIIb MS study on evobrutinib — spurring plenty of questions
Merck KGaA posts mixed data from their big PhIIb MS study on evobrutinib — spurring plenty of questions
Endpoints
Merck KGaA
evobrutinib
MS
multiple sclerosis
Flag link:
Gilenya beats Copaxone head-to-head at higher dose, study finds
Gilenya beats Copaxone head-to-head at higher dose, study finds
Biopharma Dive
Novartis
Teva Pharmaceutical
MS
Copaxone
Gilenya
Flag link:
Can Sanofi's new long-term Lemtrada data amp up sales in a crowded MS field?
Can Sanofi's new long-term Lemtrada data amp up sales in a crowded MS field?
Fierce Pharma
Sanofi
Lemtrada
MS
multiple sclerosis
Flag link:
Roche and Novartis Strengthen Their Presence in the MS Market
Roche and Novartis Strengthen Their Presence in the MS Market
BioSpace
Genentech
Roche
Ocrevus
Novartis
siponimod
FDA
MS
multiple sclerosis
Flag link:

Pages